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A B S T R A C T
Background: Several peripheral blood cell counts and immune ratios, such as the systemic immune-inflammation
index (SII = platelet x neutrophil count/lymphocyte count) have prognostic value in patients with resectable
pancreatic cancer (PDAC). Circulating microRNAs (miRNAs) are involved in various aspects of cancer and in-
flammation. We aimed to identify measurable circulating miRNAs in PDAC patients correlating with systemic
inflammation parameters.
Methods: A total of 42 PDAC patients was included in this study: twelve in the discovery (n = 6 SII low; n = 6 SII
high) and 30 patients in the validation cohort (n = 19 SII low, n = 11 SII high). MiRNAs isolated from pre-
operative serum samples were measured with a 352 miRNA panel in the discovery cohort and individual miRNA
primers in the validation cohort, using RT-qPCR (ID3EAL assays, MiRXES).
Results: Only in the discovery cohort miR-328-3p, miR-338-3p, miR-1258 and miR-199b-5p were upregulated in
high compared to low SII patients (fold difference ≥ 2, P < 0.05). In the total cohort (n = 42) correlations were
found between miR-338-3p (r = 0.48, P = 0.002) and miR-199b-5p (r = 0.44, P = 0.005) and the absolute
neutrophil count.
Conclusion: Circulating miR-338-3p and miR-199b-5p are correlated to the neutrophil count in the blood of
PDAC patients, suggesting a potential role of circulating miRNAs in cancer immune evasion and systemic in-
flammation.
1. Introduction
Pancreatic cancer (PDAC) has a poor prognosis. Only 10% of pa-
tients presents with stage I resectable disease and although their
prognosis is much better compared to patients with advanced disease,
5-year overall survival (OS) of stage I disease is only 34% [1]. More-
over, the mortality and morbidity of pancreatic tumor resection is high
[2] and 80% of resected patients have disease recurrence within two
years [3]. Patient stratification for therapy, such as surgical resection, is
important to prevent patients from receiving inefficacious treatment
and related complications.
Several studies have shown that immune cell counts, for example
absolute neutrophil or lymphocyte counts, and immune cell ratios in
the peripheral blood are of prognostic and predictive value in pan-
creatic cancer [4,5]. The number of neutrophilic granulocytes is
associated with a shorter OS in patients with resectable disease and
locally advanced PDAC [6]. Similarly, the neutrophil-to-lymphocyte
ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the systemic
immune-inflammation index (SII) are associated with poor prognosis in
patients with resectable and non-resectable PDAC [7–10]. The SII was
introduced by Hu et al. and is a ratio of the circulating platelet (P),
neutrophil (N) and lymphocyte (L) counts (SII = P × N/L) [11]. The
reference value of the SII is 459, based on a population-based pro-
spective cohort study of individuals in the Netherlands aged 65.9 years
on average [12]. The SII was found to be a prognostic marker for
cancer-specific survival and disease recurrence in resectable PDAC and
seems to outperform other immune ratios, such as the NLR [9,10]. A
high SII (> 900) before resection is associated with worse prognosis
compared to a low SII (≤900) before resection [9]. However, the un-
derlying mechanism of an altered immune system reflected by an
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increased SII leading to poorer prognosis in PDAC remains unclear.
Cell-free circulating microRNAs (miRNAs) are small non-coding
RNAs that regulate gene expression [13]. In the context of cancer,
miRNAs play a role in several processes, such as apoptosis, cell pro-
liferation, tumor suppression and immune response [13–15]. The ma-
jority of circulating miRNAs originates from endothelium and blood
cells, including leukocytes and platelets [16]. Serum miRNAs mostly
target immune related mRNAs [17]. Therefore, circulating miRNAs
could reflect the status of the immune system.
In this study, we aim to identify differentially expressed miRNAs in
the serum of resectable PDAC patients to explore the role of miRNAs in
systemic inflammation.
2. Materials and methods
2.1. Patients and samples
Treatment-naïve patients with resectable PDAC were retrospectively
identified based on availability of preoperative serum and absolute
leukocyte and platelet counts. All patients underwent surgical resection
of the primary tumor within the Erasmus University Medical Center
Rotterdam in the period of February 2013 – December 2017.
Peripheral venous blood samples from PDAC patients were collected
preoperatively on the day of surgery or up to five days prior to surgery.
This study was approved by the Medical Ethics Committee of the
Erasmus University Medical Center Rotterdam for which all patients
had provided written informed consent (MEC-2015-085). Blood was
collected in serum tubes with clot activator of silica particles (BD,
Franklin Lakes, NJ). None of the patients showed signs of infection that
might indicate, for example, cholangitis or pancreatitis at time of blood
collection. After collection, blood samples were centrifuged for ten
minutes at 2000 g, and serum was stored at −80 °C until further use.
Absolute circulating neutrophil, lymphocyte, and platelet counts
were measured as part of standard preoperative patient care. SII values
were calculated as the absolute platelet count, multiplied by the abso-
lute neutrophil to absolute lymphocyte ratio (SII = P × N/L). Patients
were grouped as low SII (median 592.0, interquartile range
451.6–720.3) and high SII (median 1227.7, interquartile range
1054.4–2016.4), based on the cutoff value of 900 determined by Aziz
et al. SII values closest to the time of surgery were used for analysis. A
total of 42 serum samples were available for this study. Twelve serum
samples were used in the discovery cohort, six with the lowest SII and
six with the highest SII, to select miRNAs for validation and correlation
analyses. The remaining 30 serum samples, including 19 with a low SII
and 11 with a high SII, were used in the validation cohort.
In this study, SII low patients were considered the control group. No
other control samples were included, such as samples from chronic
pancreatitis patients, because of the lack of evidence concerning the
prognostic value of the SII in this patient group.
2.2. Serum miRNA isolation and quantitation
In the discovery cohort, RNA was isolated from 2 × 200 µL serum
using the miRNeasy serum/plasma miRNA Isolation Kit (Qiagen,
Hilden, Germany) in order to reach sufficient RNA volume for reliable
measurement of 384 miRNA targets. In the validation cohort only 20
targets were measured and therefore RNA was isolated from 200 µL
serum using the same isolation kit. In the validation cohort, two pro-
prietary pre-mixed spike-in ~20 nucleotide control RNAs (MiRXES,
Singapore) with sequences distinct from annotated mature human
miRNAs (miRbase version 21) were added to the lysis buffer prior to the
serum miRNA isolation according to manufacturer’s instructions, in
order to evaluate RNA isolation efficiency.
In the discovery cohort, serum miRNAs were reverse transcribed
(RT) using ID3EAL miRNA-specific oligo’s and RT spike-in RNA
(MiRXES, Singapore) in a multiplex reaction per manufacturer’s
instruction. Complementary DNA (cDNA) was stored at −20 °C up to
two weeks and thawed only once. cDNA was added to the ID3EAL
miRNA qPCR Master Mix, containing buffer, polymerase and the pas-
sive reference dye ROX, and transferred to pre-loaded ID3EAL 384
Target Assay Panel plates (MiRXES, Singapore), including 352 in-
dividual quantitative polymerase chain reaction (qPCR) primers, 16 RT
spike-ins and 16 inter-plate controls. PCR amplification was performed
with the 7500 Fast Real-Time PCR system (Applied Biosystems, Foster
City, CA, USA). Raw threshold cycle (Ct) values were determined using
the 7500 Software (version 2.3; Applied Biosystems, Foster City, CA,
USA).
In the validation cohort, selected serum miRNAs were measured
with ID3EAL RT-qPCR after reverse transcription, using individual
miRNA primers (MiRXES, Singapore). Raw threshold cycle (Ct) values
were determined using the 7500 Software (version 2.3; Applied
Biosystems, Foster City, CA, USA) and the serum miRNA samples were
measured in duplicate.
2.3. Statistical analyses
Patient characteristics were compared using a Chi-square test for
categorical and Mann-Whitney U test for numeric data. Progression-free
survival (PFS) and cancer-specific survival (CSS) were calculated as the
time between resection and radiologically confirmed progression or
death caused by progression of the disease, respectively, comparing
Kaplan-Meier curves with log-rank tests. Statistical analyses were per-
formed with SPSS Statistics for Windows (version 24.0; IBM, Armonk,
NY, USA) and Prism for Windows (version 5.01; GraphPad Software,
San Diego, CA, USA).
In the discovery cohort, raw Ct values were normalized using re-
ference miRNAs, spike-ins, and inter-plate calibrators, using an algo-
rithm incorporated in the Cancer Panel Analysis Template (version 1.9,
MiRXES, Singapore), provided by the manufacturer. The two miRNAs
with the most stable expression among all samples were selected as
reference miRNAs, using NormFinder software for Excel (version 0.953;
MOMA, Aarhus University Hospital, Denmark). The cutoff values for
detection of raw Ct values were set at a minimum of 9 and maximum of
33 cycles, based on the manufacturer’s recommendation. The average
miRNA expression of the low and high SII samples were compared with
a two-tailed t-test.
Differentially expressed miRNAs between the high SII and low SII
patients with a fold difference of ≤0.5 or ≥2, for downregulated or
upregulated miRNAs respectively, and P < 0.05, that were detectable
within the Ct value limits in all 12 patient samples, were selected for
validation and continuous correlation analyses.
In the validation cohort, raw Ct values were normalized using the
same two reference miRNAs from the discovery cohort. MiRNA ex-
pression relative to the reference miRNAs was calculated with the delta
Ct method; expression = 2−(Ct miRNA of interest – average Ct reference miRNAs).
The average miRNA expression was compared between patient groups
using a two-tailed t-test.
Correlations between miRNA expression and SII or individual ab-
solute blood cell counts were measured by Pearson’s correlation coef-
ficient, using all patient samples, measured with individual qPCR. An
univariate Cox regression analysis was conducted to evaluate the as-
sociation between miRNA expression and CSS and PFS.
3. Results
3.1. Patient characteristics
A total of 42 treatment-naïve resectable PDAC patients were in-
cluded in this study of whom serum was available and peripheral blood
cell counts were measured before tumor resection at the Erasmus
University Medical Center. No differences in patient characteristics
were observed between the discovery cohort and validation cohort. In
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addition, no differences in patient characteristics were observed be-
tween SII low and SII high patients, except for the SII and absolute
lymphocyte count, which was of course used to differentiate between
patient groups. Patient characteristics are summarized in Table 1.
3.2. Differential serum miRNA expression in the discovery cohort
From the total cohort of PDAC patients, six patients with the highest
SII values, and six patients with the lowest SII values were selected for
serum miRNA discovery. Fig. 1 shows a scheme of the miRNA study
design. A list of miRNAs included in the discovery ID3EAL Cancer
miRNA Knowledge panel can be found in Supplementary Table 1. Out
of 352 miRNAs, 207 were detectable within the Ct limits in all twelve
serum samples. Four differentially expressed miRNAs (DE miRNAs)
showed a fold difference ≥ 2 and P < 0.05 between the high SII and
low SII group (Table 2). These four miRNAs were upregulated in the
high SII group and were selected for validation in n = 30 additional
patients. In the miRNA discovery samples we found that miR-345-5p
and miR-130b-5p had the best stability and were selected as reference
miRNAs for the validation cohort.
3.3. Serum miRNA expression in the validation cohort
In one out of 30 patient samples of the validation cohort we could
not detect the four miRNAs of interest or the reference miRNAs by RT-
qPCR and this sample was therefore excluded from further analysis.
MiR-1258 was not detected in 10/60 meafvsurements (17%), in both
the low SII as well as the high SII patients. None of the four selected
miRNAs remained significantly upregulated between high SII and low
SII patients in the independent validation set (Table 3). In contrast to
our findings in the discovery cohort, miR-328-3p showed a significant
downregulation in patients with high SII compared to low SII
(P = 0.022).
3.4. Serum miRNA expression association with blood cell counts and
survival
In addition to using an SII cutoff of 900 to separate the two patient
groups, we calculated the correlations between expression data of miR-
338-3p and miR-199b-5p and the SII and individual immune cell counts
(Fig. 2). Two miRNAs were excluded from these analyses: miR-328-3p
was excluded due to discrepancy in expression directionality between
the discovery and validation cohort and miR-1258 was excluded due to
the lack of detection.
There was a significant correlation between serum miR-338-3p
(Fig. 2a) and the absolute neutrophil count (r = 0.48, P = 0.002) as
well as between serum miR-199b-5p (Fig. 2b) and the absolute neu-
trophil count (r = 0.44, P = 0.005). Neither miR-338-3p or miR-199b-
5p showed a significant correlation between serum expression and the
SII (P = 0.185 and P = 0.145), the absolute lymphocyte count




Discovery cohort (n = 12) Validation cohort (n = 30) P-value SII low (n = 25) SII high (n = 17) P-value
Age (years), median (range) 70.0 (58–84) 69.5 (46–88) 0.466 68.0 (49–88) 71.0 (46–87) 0.635
Gender (%)
Male 10 (83.3) 22 (73.3) 0.492 19 (76.0) 13 (76.5) 0.972
Female 2 (16.7) 8 (26.7) 6 (24.0) 4 (23.5)
SII (%)
Low (≤900) 6 (50.0) 19 (63.3) 0.426 25 (1 0 0) 0 (0) NA
High (> 900) 6 (50.0) 11 (36.7) 0 (0) 17 (1 0 0)
SII, median (IQR) 1139.8(398.5–2171.1) 744.0(592.5–1051.3) 1.000 592.0(451.6–720.3) 1227.7(1054.4–2016.4) < 0.001
Absolute neutrophil count, median (IQR) 4.9 (3.4–8.1) 5.1 (4.4–5.6) 0.808 4.6 (3.6–5.3) 5.5 (4.8–7.0) 0.059
Absolute lymphocyte count, median (IQR) 1.3 (0.9–2.2) 1.7 (1.3–2.3) 0.353 2.2 (1.5–2.5) 1.1 (0.9–1.6) 0.012
Platelet count, median (IQR) 252.0(183.8–346.8) 291.0(238.0–326.0) 0.353 273.0(219.5–302.5) 303.0(240.5–380.0) 1.000
Bilirubin, median (IQR) 15.0 (7.5–54.3) 21.0 (9.5–29.5) 0.794 14.0 (8.5–28.5) 24.0 (9.5–51.5) 0.174
Tumor marker 200.0 47.0 0.258 40.0 82.0 0.530
CA19-9, median (IQR) (25.6–348.0) (20.5–299.0) (20.0–305.5) (38.5–334.5)
Tumor location (%)
Head 10 (83.3) 29 (96.7) 0.135 23 (92.0) 16 (94.1) 0.418
Body 0 (0) 1 (3.3) 1 (4.0) 0 (0)
Tail 1 (8.3) 0 (0) 1 (4.0) 0 (0)
Multifocal 1 (8.3) 0 (0) 0 (0) 1 (5.9)
T-stagea (%)
1 1 (8.3) 2 (6.7) 0.850 2 (8.0) 1 (5.9) 0.794
2 0 (0) 0 (0) 0 (0) 0 (0)
3 11 (91.7) 28 (93.3) 23 (92.0) 16 (94.1)
4 0 (0) 0 (0) 0 (0) 0 (0)
N-stagea (%)
0 4 (33.3) 7 (23.3) 0.505 6 (24.0) 5 (29.4) 0.695
1 8 (66.7) 23 (76.7) 19 (76.0) 12 (70.6)
2 0 (0) 0 (0) 0 (0) 0 (0)
Tumor differentiation (%)
Good 0 (0) 0 (0) 0.395 0 (0) 0 (0) 0.497
Moderate 9 (75.0) 17 (56.7) 17 (68.0) 9 (52.9)
Poor 3 (25.0) 10 (33.3) 6 (24.0) 7 (41.2)
Unknown 0 (0) 3 (10.0) 2 (8.0) 1 (5.9)
Adjuvant chemotherapyb (%) 6 (50.0) 10 (33.3) 0.315 14 (56.0) 12 (70.6) 0.339
CSS (months), median (95% CI) 22.0 18.0 0.666 20.0 16.0 0.484
(6.6–37.4) (16.7–19.3) (15.9–24.1) (12.0–20.0)
PFS (months), median (95% CI) 20.0 13.0 0.457 14.0 13.0 0.455
(11.5–28.5) (11.3–14.7) (12.2–15.8) (10.6–15.5)
SII = systemic immune-inflammation index; IQR = interquartile range; CSS = cancer-specific survival; CI = confidence interval; PFS = progression free survival.
a T- and N-stage classification according to AJCC 7th edition.
b Standard adjuvant chemotherapy consisted of six cycles of gemcitabine.
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To evaluate whether miR-338-3p and miR-199b-5p also show a
correlation with survival, univariate Cox regression analyses were
performed. There were no significant correlations between miR-338-3p
and CSS (HR = 2.672, P = 0.549) or PFS (HR = 4.384, P = 0.350) or
between miR-199b-5p and CSS (HR = 2.241, P = 0.705) or PFS
(HR = 5.279, P = 0.432), as shown in Table 4.
4. Discussion
PDAC progression has been linked with the host’s systemic in-
flammatory response and circulating blood cells [9,18]. This is the first
study that attempts to identify a circulating miRNA signature related to
the altered SII and immune cell counts in PDAC patients. MiRNAs are
heavily involved in immune cell proliferation, differentiation and
function [17,19,20]. Cell-free miRNAs in the circulation are primarily
derived from blood cells and the endothelium [16]. Circulating miRNAs
have potential as cancer biomarkers due to their stability in plasma or
serum, their roles in cell-cell contact and regulation of cellular pro-
cesses [21]. Although no correlation between the SII and any of the four
miRNAs could be validated in our cohort, there was a statistically sig-
nificant correlation between miR-338-3p and miR-199b-5p expression
and the absolute neutrophil count. Whether miR-338-3p and miR-199b-
5p are also upregulated in circulating neutrophils or tumor infiltrating
neutrophils in PDAC patients needs to be investigated in the near fu-
ture.
Neutrophilia is associated with a poor prognosis in PDAC [18,22]
but the underlying mechanism is unknown. The chronic state of in-
flammation may well lead to an influx of immunosuppressive neu-
trophils into tumors [23] that recruit regulatory T cells in the tumors
[24]. Immunosuppressive neutrophils generate high levels of reactive
oxygen species (ROS) which blocks T cell proliferation [25] and can
also induce CD8 T cell apoptosis through secretion of nitric oxide [26].
MiR-338-3p has not yet been described for its association with neu-
trophils or PDAC. However, miR-338-3p expression was found to be
upregulated in leukocytes derived from patients with sporadic amyo-
trophic lateral sclerosis, showing that the disease related transcriptional
miRNA alterations exist in tissues outside of the affected organ system
[27]. Upregulation of miR-338-3p was also found in peripheral blood
mononuclear cells of patients with pemphigus vulgaris, where it sup-
presses cell viability [28]. Whereas miR-338-3p is upregulated in the
circulation in a limited number of studies, miR-338-3p is often down-
regulated in cancer tissues. Because of its tumor suppressing function,
Fig. 1. Schematic overview of serum miRNA analysis. In the discovery cohort n = 12 patients with resectable pancreatic cancer with low or high systemic immune-
inflammation index (SII) were analyzed using an RT-qPCR based 352 cancer miRNA panel from MiRXES to identify differentially expressed miRNAs (DE miRNAs).
Statistical significance was calculated using a two-tailed t-test. Four DE miRNAs were measured in the validation cohort. RT = reverse transcription.
Table 2
Differentially expressed serum miRNAs in high SII versus low SII patients in the
discovery cohort (n = 12) that were selected for validation.






Differences in serum expression of the four selected miRNAs in high SII versus
low SII patients of the validation cohort (n = 30).
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downregulation of miR-338-3p in cancer tissue samples was proven to
be a poor prognostic factor in several cancers, such as gastric, and
prostate cancer [29,30].
In a recent study miR-199b-5p expression in PDAC tissue was also
linked with poor prognosis [31]. However, it remains unclear whether
miR-199b-5p originates from the cancer cells themselves or from other
cell types. Others have shown that the miR-199 family, including miR-
199b, is primarily expressed in the fibrotic tumor associated stroma in
PDAC tissues [32]. MiR-199b findings are inconsistent across studies in
different cancers. For instance in cervical cancer, miR-199b-5p over-
expression is associated with poor prognosis and metastasis [33], while
in other cancers such as breast, and colorectal cancer miR-199b-5p has
a tumor suppressor function and poor prognosis is reflected by a de-
crease of expression [34,35]. MiR-199b is overexpressed in myeloid
progenitor cells and expression levels drop along with differentiation of
these cells [36]. While in some studies miR-199b levels are reportedly
upregulated in plasma of acute myeloid leukemia (AML) patients
compared to healthy controls [37], in other studies high levels of miR-
199b were found favorable in terms of OS of AML patients [36]. In
sepsis patients, miR-199b-5p was specifically upregulated in blood cells
(including neutrophils), but this difference in expression could not be
detected in the serum [38]. Until now, the exact origin of disease-re-
lated circulating miRNAs remains unclear. Once in the circulation,
miRNAs are transferred to various cell types where they can alter gene
Fig. 2. Continuous relationship between serum miR-338-3p (a) and miR-199b-5p (b) expression and the systemic immune-inflammation index (SII) or individual
absolute blood cell counts in the total cohort of patients (n = 42). Serum miRNA expression is relative to the average expression of reference miRNAs. r = correlation
coefficient, P-value is calculated by Pearson’s r correlation.
Table 4
Univariate Cox regression analysis of miR-338-3p and miR-199b-5p expression for cancer-specific survival (CSS) and progression-free survival (PFS) in patients with
resectable pancreatic cancer.
MicroRNA Hazard ratio* for CSS (95% CI) P-value Hazard ratio* for PFS (95% CI) P-value
hsa-miR-338-3p 2.672 (0.107–66.579) 0.549 4.384 (0.198–97.144) 0.350
hsa-miR-199b-5p 2.241 (0.035–145.355) 0.705 5.279 (0.083–333.937) 0.432
* Hazard ratio for every 1 unit change, where each unit represents a change of 1.0 fold difference over reference miRNA expression. CI = confidence interval.
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expression depending on the cellular context and targeted organ
[39,40].
MiRNA target prediction using the online database miRDB [41]
showed that in general miR-338-3p has 601 predicted mRNA targets.
The gene with the highest target score for miR-338-3p is Casitas B-
lineage Lymphoma Proto-oncogene (CBL), which is a key player in
balancing of the immune response and considered a potential target for
anticancer immune therapy [42]. In neutrophils specifically, c-CBL
mediates the termination of FcγRIIa signaling, resulting in down-
regulation of neutrophil function [43]. For miR-199b-5p there are 556
predicted mRNA targets, from which Discoidin Domain Receptor Tyr-
osine Kinase 1 (DDR1) has the highest target score. DDR1 is known as a
collagen receptor on leukocytes which plays a role in the physical at-
tachment of leukocytes to collagen, as well as the differentiation and
cytokine/chemokine production of cells of the myeloid lineage [44].
These findings suggest that miR-338-3p and miR-199b-5p could exert
pivotal roles in the regulation of immune related gene expression.
The ID3EAL qPCR assay from MiRXES used in our study is a sen-
sitive method for measuring serum miRNAs. This method utilizes
miRNA-specific reverse transcription as well as a combination of a
miRNA-specific forward and reverse primers. Two hundred and seven
miRNAs included in the 352 miRNA panel were detected in all twelve
discovery serum samples. This is higher than in qPCR microarrays
without the use of miRNA-specific RT primers and is comparable to
more advanced techniques, such as next generation sequencing and
digital count technologies [45].
The main limitation of this retrospective study is the low number of
patient samples. All patient samples had previously been collected from
treatment-naïve patients, as part of our local blood sample biobank.
Despite the large number of collected blood samples, only 42 serum
samples were available for this study, due to missing data on absolute
immune cells counts. For future studies, we are aiming to prospectively
collect all data on, for example, immune cell counts, immune cell ratios
and tumor markers in addition to blood samples for circulating bio-
marker analyses.
A significant prognostic value of the SII or circulating neutrophil
counts could not be confirmed in this experiment. In addition, none of
the investigated miRNAs showed an association between expression
levels and survival, although there is a trend visible towards increased
hazard ratios for CSS and PFS with increased expression of miR-338-3p
and miR-199b-5p. The small sample size, causing wide confidence in-
tervals, could explain the lack of statistical significance. Another un-
expected finding is the discrepancy of miR-328-3p expression between
the discovery and validation cohort, which might be explained by the
high variability of miRNA expression in low SII patients. Although the
SII cutoff value of 900 has been validated for its prognostic value in
multiple studies, the SII might not be a good marker to differentiate
between patient subgroups on a molecular level. However, the four
miRNAs in the validation cohort of this study were selected based on
the differential expression between low and high SII dichotomization.
In retrospect, miRNA selection could have been improved by using, for
example, the absolute neutrophil count to distinguish the two patient
groups.
In conclusion, we aimed to identify serum miRNA signatures that
are related to systemic inflammation in PDAC patients. Serum miR-338-
3p and miR-199b-5p were found to be significantly correlated to the
absolute neutrophil count in patients with resectable PDAC. Our find-
ings support the potential role of miRNAs in the altered immune system
of pancreatic cancer patients. Future research regarding circulating
miRNAs in PDAC patients could elucidate whether miRNAs can serve as
therapeutic target by altering immune related intercellular commu-
nication and reversing cancer immune evasion.
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